Time to Progression in Metastatic Breast Cancer Patients Treated With Epirubicin Is Not Improved by the Addition of Either Cisplatin or Lonidamine: Final Results of a Phase III Study With a Factorial Design - Concepedia

Concepedia

Publication | Closed Access

Time to Progression in Metastatic Breast Cancer Patients Treated With Epirubicin Is Not Improved by the Addition of Either Cisplatin or Lonidamine: Final Results of a Phase III Study With a Factorial Design

83

Citations

31

References

2002

Year

Alfredo Berruti, Raffaella Bitossi, G. Gorzegno, Alberto Bottini, P Alquati, A. De Matteis, Francesco Nuzzo, Giorgio Giardina, Saverio Danese, Mario De Lena,

Journal of Clinical Oncology

Abstract

Neither CDDP nor LND was able to significantly improve the time to progression obtained by EPI. CDDP, however, significantly worsened the drug's tolerability.

References

	Year	Citations

Page 1